Spreadsheet: a9b16496-0d8d-4786-9e29-b9efc5519472
Sheet: Sheet1

Effects of propranolol-containing drug combinations on growth of P. falciparum and [NAME] | Unnamed: 1 | Unnamed: 2 | Unnamed: 3 | Unnamed: 4 | Unnamed: 5 | Unnamed: 6 | Unnamed: 7 | Unnamed: 8 | Unnamed: 9
3D7 | IC50 Prop | IC50 Prop slope | IC50 [NAME] | IC50 CQ slope | IC90 Prop | IC90 Prop slope | IC90 [NAME] | IC90 CQ slope | Chloroquine Reduction
 | ([NAME]) | (Δviability/Δprop) | (nM) | (Δviability/ΔCQ) | ([NAME]) | (Δviability/Δprop) | (nM) | (Δviability/ΔCQ)
CQ alone |  |  | 28.91 | -3.24 |  |  | 58.08 | -0.35
3CQ:1Prop | 1.23 | -70.55 | 14.74 | -5.89 | 3.08 | -4.09 | 37 | -0.34
1CQ:1Prop | 1.47 | -54.25 | 5.87 | -13.58 | 3.54 | -4.51 | 14.16 | -1.13
1CQ:3Prop | 2.15 | -63.25 | 2.87 | -47.41 | 3.95 | -4.46 | 5.27 | -3.34 | 10-fold reduction in IC50
Prop alone | 2.19 | -49.06 |  |  | 4.6 | -3.52 |  |  | 11-fold reduction in IC90
FCB | IC50 Prop | IC50 Prop slope | IC50 [NAME] | IC50 CQ slope | IC90 Prop | IC90 Prop slope | IC90 [NAME] | IC90 CQ slope | Chloroquine Reduction
 | ([NAME]) | (Δviability/Δprop) | (nM) | (Δviability/ΔCQ) | ([NAME]) | (Δviability/Δprop) | (nM) | (Δviability/ΔCQ)
CQ alone |  |  | 63.17 | -1.22 |  |  | 122.21 | -0.19
3CQ:1Prop | 1.11 | -88.21 | 26.71 | -3.67 | 2.63 | -4.74 | 63.23 | -0.2
1CQ:1Prop | 1.21 | -129.68 | 9.66 | -16.29 | 2.74 | -3.3 | 21.92 | -0.41
1CQ:3Prop | 2.25 | -71.9 | 5.99 | -27.06 | 4.47 | -2.81 | 11.92 | -1.05 | 10.5-fold reduction in IC50
Prop alone | 2.21 | -15.1 |  |  | 13.31 | -0.76 |  |  | 10.3-fold reduction in IC90
3D7 | IC50 Prop | IC50 Prop slope | IC50 Art | IC50 Art slope | IC90 Prop | IC90 Prop slope | IC90 Art | IC90 Art slope | Artemisinin Reduction
 | ([NAME]) | (Δviability/Δprop) | (nM) | (Δviability/Δart) | ([NAME]) | (Δviability/Δprop) | (nM) | (Δviability/Δart)
Art alone |  |  | 3.22 | -33.22 |  |  | 6.41 | -2.79
3Art:1Prop | 0.76 | -97.74 | 2.27 | -32.74 | 2.21 | -5.12 | 6.64 | -1.7
1Art:1Prop | 1.28 | -66.75 | 1.28 | -66.75 | 3.01 | -5.12 | 3.01 | -5.12
1Art:3Prop | 1.69 | -48.54 | 0.56 | -146.3 | 4.38 | -2.89 | 1.46 | -8.67 | 5.8-fold reduction in IC50
Prop alone | 2.03 | -57.64 |  |  | 4 | -4.29 |  |  | 4.4-fold reduction in IC90
P. berghei | IC50 Prop | IC50 Prop slope | IC50 [NAME] | IC50 CQ slope | IC90 Prop | IC90 Prop slope | IC90 [NAME] | IC90 CQ slope | Chloroquine Reduction
 | (mg/kg/d) | (Δviability/Δprop) | (mg/kg/d) | (Δviability/ΔCQ) | (mg/kg/d) | (Δviability/Δprop) | (mg/kg/d) | (Δviability/ΔCQ)
CQ alone |  |  | 1.64 | -45.55 |  |  | 3.48 | -8.1
2CQ:1Prop | 1.63 | -17.76 | 1.21 | -55.87 | 6.3 | -3.11 | 3.06 | -6.4
1CQ:1Prop | 3.95 | -12 | 1.05 | -61.78 | 11.28 | -1.26 | 2.14 | -12.37
1CQ:2Prop | 4.19 | -5.74 | 0.66 | -68.52 | 18.21 | -1.15 | 1.93 | -13.01 | 2.5-fold reduction in IC50
Prop alone | 7.18 | -3.86 |  |  | ND | ND |  |  | 1.8-fold reduction in IC90
Key:
IC50 = drug concentration at 50% viability of control; IC90 = drug concentration at 10% viability of control
Prop, propranolol; [NAME], chloroquine; [NAME], artemisinin; NA, not applicable; ND, no data
Δviability measured by hypoxanthine incorporation vs. control for P. falciparum 3D7 and FCB and by counting Giemsa-stained blood smears for [NAME] (see Methods)
Δprop, ΔCQ, Δart refers to change in drug concentration
Reduction indicates drop in drug concentration ([NAME] or [NAME]) needed to achieve the IC50 or IC90 in highest propranolol-containing combinations compared to [NAME] or [NAME] alone